Archive for the Category » Job Opportunities «

Tuesday, April 06th, 2010 | Author: admin

There are many types of analyses that help to illuminate potential issues as well as areas of opportunity for a new business – one is known as a SWOT or Strengths – Weaknesses – Opportunities and Threats analysis.   This type of analysis forces the executive team of any pharmaceutical company to brainstorm these critical items before launching a new company, new division or new product – which may help decide whether or not to venture into this new direction.

Strengths are attributes that are unique to the company, product or division in question.  Some examples of strengths would be having a key scientist on your team that has a unique skill set or knowledge that will make your new product a success.  Other strength examples include patents, knowledge of a particular niche area, and manufacturing advances that allow you to create something that was not readily available in the past.

Weaknesses are just the opposite – some examples include lack of a patent or relying on unpatented discoveries, having no clear manufacturing process or significant process issues, or not having talent specific to the area you are moving towards.   Weaknesses are pointed out as areas to be addressed.

Opportunities would include an increase in the disease group that your new product is expected to address, the opening of a new global market that the product can fulfill , or a new federal grant to help subsidize the cost of your new drug or treatment.  Once opportunities are identified, a plan to take advantage of them should be created.

Threats could include clinical trials in this area by other competing companies, new regulations that would make it difficult to get approval, adverse press garnered by any preannouncements of what you are working on, or a loss of any type of funding for the project.  Threats may or may not be real – but contingency plans to address them should be in place.

A SWOT analysis of your main competitor’s position is an opportunity to demonstrate your strategic position to senior management or potential investors as part of your business plan.  It can also be a way of presenting to investors that you have mapped out the landscape for your potential product, and can both address the opportunities and eliminate or at least appropriately address the threats.   If properly mapped, each can be a consolidated  table in your plan which makes it very easy to communicate your intentions to the investors or management teams authorizing the necessary financial resources to execute the plan..

Pharmaceutical consultants can help you prepare this type of analysis to assess any new business decision you may be facing, or as part of a comprehensive business plan for a new pharmaceutical business you are launching.  Their experience, expertise, and industry insights can serve as a tremendous boost to your new venture.   Once they have helped you brainstorm these key areas, they can also help you formulate comprehensive plans for action in each of the four areas of the analysis.

If you liked this article, tell all your friends about it. They’ll thank you for it. If you have a blog or website, you can link to it or even post it to your own site (don’t forget to mention www.smartconsultinggroup.com as the original source).

Share This Post
Thursday, January 28th, 2010 | Author: admin

FTC Commissioner J. Thomas Rosch will speak about the three main areas of antitrust concern for pharma manufacturers, at ACI’s 5th Annual In-House Counsel Forum on Pharmaceutical Antitrust, to take place at the Helmsley Park Lane Hotel in New York City on February 17th and 18th, 2010.

The three areas he will cover are:

-    Reverse settlement payments
-    Authorized genetics
-    Pharmaceutical mergers

In past months, a consensus position by DOJ and the FTC has been noticed on antitrust matters.  In fact, DOJ took back its previous position on reverse settlement agreements, and currently, both organizations consider these agreements anticompetitive.  There is pending legislation that could define, by itself, a prohibition on these agreements if several circumstances are not present.  This shows that the Congress is supporting the antitrust efforts of both organizations in the pharma industry.  Moreover, the European Commission’s Directorate General’s Pharmaceutical Sector Inquiry report adds a more global scope to this dense field.

The Director of the FTC’s Bureau of Competition, Richard Feinstein, along with FTC attorneys Markus Meier, Assistant Director of the Health Care Division, and Michael Moiseyev, Assistant Director of the Mergers l Division, will speak at this event, which is recognized as the place where the leading antitrust authorities meet every year to discuss their upcoming enforcement plans.  Also participating will be Philip Weiser, Deputy Assistant Attorney General from the DOJ’s Antitrust Division, and Harald Mische, member of the EC’s DG Competition’s Pharmaceutical Task Force.

Sunsieray McCall, ACI’s Senior Conference Producer, recalls that the attendance of antitrust enforcers from both the U.S. and EU will offer this conference’s attendees a deep understanding of antitrust priorities under a new global enforcement system.

If you want to know more about ACI’s 5th Annual In-House Counsel Forum on Pharmaceutical Antitrust, contact your life sciences consulting firm, visit American Conference/ PharmaAntitrust, or contact Sunsieray McCall directly at s.mccall@americanconference.com or at the phone number 212-352-3220, ext. 498.

If you liked this article, tell all your friends about it. They’ll thank you for it. If you have a blog or website, you can link to it or even post it to your own site (don’t forget to mention www.smartconsultinggroup.com as the original source).

Share This Post
Thursday, July 02nd, 2009 | Author: admin

Smart Consulting Group is looking for consultants of varied experience to work with clients teams to develop project plans, assist with policy development, prepare working proposals and to provide technical support to facilitate the development of new products.

Consultants should have a BS degree and preferably an advanced scientific degree with experience in biotechnology/pharmaceutical product development & manufacturing.

Experience in all scientific disciplines which support these activities are of interest including but not necessarily limited to: molecular biology, cell culture, fermentation, downstream processing, protein purification/purification, fill finish, manufacturing operations planning, supply chain, drug policy development & project/program management.
Smart Consulting Group is looking for enthusiastic, energetic highly motivated self starter professionals that have well-developed interpersonal skills and have a desire to contribute at the highest level of their professional capabilities to make a difference.
We require individuals that can work independently and as part of an integrated team & have a well-developed sense of personal time management.
Salary/compensation will be commensurate with industry competitive rates.

Location: the DC/Mid-Atlantic Region and remote travel locations.
Travel may be required for some assignments.

To send resumes/request additional information contact
inquiries@Smartconsultinggroup.com

Share This Post
Wednesday, May 20th, 2009 | Author: admin

Responsibilities:

Coordinates all activities associated with the companies Smart Learning Academy courses.

Assists in the development of commercial and governmental customers

Assists in sales & marketing of Smart Consulting Group products including:

  • Consulting services
  • Training courses
  • Specific electronic media.

Qualifications:

Experience: Individual must have a proven track record in sales and marketing as well as program coordination. Experience in the Life Sciences/Healthcare field would be an advantage.

Education: Preferred technical qualifications would include a bachelor’s degree in business/marketing or related field.

Share This Post
px